Jump Financial LLC Takes $522,000 Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jump Financial LLC purchased a new position in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 32,375 shares of the company’s stock, valued at approximately $522,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Deerfield Management Company L.P. Series C boosted its position in Deciphera Pharmaceuticals by 2.8% during the third quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company’s stock worth $87,738,000 after purchasing an additional 190,580 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Deciphera Pharmaceuticals in the 3rd quarter worth about $1,188,000. Deutsche Bank AG grew its stake in Deciphera Pharmaceuticals by 36.7% in the 3rd quarter. Deutsche Bank AG now owns 254,671 shares of the company’s stock valued at $3,239,000 after acquiring an additional 68,435 shares during the last quarter. Fisher Asset Management LLC purchased a new position in Deciphera Pharmaceuticals during the 4th quarter valued at about $1,006,000. Finally, Armistice Capital LLC raised its position in Deciphera Pharmaceuticals by 1.1% during the third quarter. Armistice Capital LLC now owns 4,612,000 shares of the company’s stock worth $58,665,000 after acquiring an additional 52,000 shares during the last quarter. Institutional investors and hedge funds own 70.96% of the company’s stock.

Analysts Set New Price Targets

DCPH has been the topic of several research reports. Barclays upgraded shares of Deciphera Pharmaceuticals from an “underweight” rating to an “equal weight” rating and increased their price target for the company from $9.00 to $26.00 in a research report on Tuesday, April 30th. Leerink Partnrs downgraded Deciphera Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, April 29th. Jonestrading restated a “hold” rating and issued a $25.60 price objective on shares of Deciphera Pharmaceuticals in a research report on Monday, April 29th. JPMorgan Chase & Co. lifted their price objective on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 20th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $25.60 target price (down from $26.00) on shares of Deciphera Pharmaceuticals in a report on Monday, April 29th. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $24.17.

Deciphera Pharmaceuticals Stock Performance

NASDAQ:DCPH opened at $25.47 on Wednesday. Deciphera Pharmaceuticals, Inc. has a one year low of $9.90 and a one year high of $25.55. The business’s 50-day simple moving average is $18.64 and its 200 day simple moving average is $16.08. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -11.52 and a beta of 0.20.

Deciphera Pharmaceuticals Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.